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Summary A serological assay for the quantitative determination of the novel tumour-associated epitope CA242 was developed and used for determination of sensitivity and specificity of CA242 in gastrointestinal
cancer. The CA242 assay showed a better tumour specificity than CA50 (and CA 19-9). This was most noticeable in benign hepatobiliary disease. The sensitivity at 90% specificity cut-off level was approximately three times higher for CA242 compared to CA50 in colo-rectal cancer Dukes A, B and C, while in pancreatic
cancer the sensitivity of CA242 and CA50 was similar. CA242 was expressed independently of CEA, and the combination of CEA and CA242 gave in colo-rectal cancer considerably higher sensitivity than the use of only
one of the markers. This was most pronounced in Dukes A and Dukes B patients. CA242 is a novel tumour marker of potential clinical use, particularly in colo-rectal cancer.
Many of the novel monoclonal-antibody defined serological
tumour markers, e.g. CA 19-9, CA50, CA125, CA 15-3,
MCA, MAM-6, DUPAN-2, TAG-72 belong to the mucinous
types of glyco-proteins (Magnani et al., 1983; Lindholm et
al., 1983; Bast et al., 1981; Hilkens et al., 1983; Kufe et al.,
1983; Stahli et al., 1985; Hilkens et al., 1986; Lan et al., 1987;
Johnson et al., 1986). The mucinous glycoproteins are highly
glycosylated high molecular weight substances and may con-
tain many different carbohydrate epitopes with possible tu-
mour specificity. The CA 19-9, CA50 and CA125 assays
utilises the same antibody for catching and detecting the
antigen (Del Villano et al., 1983; Cooper et al., 1988; Klug et
al., 1984). Careful characterisation of other epitopes on the
antigens carrying these epitopes may thus lead to the dev-
elopment of assays with better clinical performance.
The use of tumour marker analyses as a diagnostic aid in
the management of cancer patients is an accepted clinical
routine in different forms of cancer (International Union
Against Cancer 1986). One disadvantage of existing tumour
markers is a relatively low tumour specificity with elevated
levels (compared to healthy subjects) commonly found in
benign diseases, which limit the use for primary diagnosis of
cancer. In order to determine the clinical utility of different
tumour markers the Working Group on Tumour Marker
Criteria (WGTMC) has concluded that if tumour markers
should be used for diagnostic purposes, the reference popula-
tion used for establishment of cut-off levels should consist of
age-matched controls and appropriate benign diseases of the
same organ(s) and/or comparable tissues (Bonfrer, 1990).
Previous papers have demonstrated that different tumour-
associated carbohydrate epitopes were co-expressed with
CA50 on a mucinous tumour associated antigen named
CanAg (Johansson et al., 1991; Johansson et al., 1991b). One
of these novel carbohydrate epitopes, CA242, has, in a
preliminary serological evaluation, increased the tumour
specificity of assays for detection of the CanAg antigen
(Johansson et al., 1991b).
In this paper, the development of a DelfiaTM assay for the
determination of CA242 is described. The clinical utility of
the CA242 tumour marker assay further evaluated by deter-
mination of tumour sensitivity and specificity in colo-rectal
and pancreatic cancer in relation to benign gastro-intestinal
disease. The sensitivity and specificity of the CA242 assay is
also compared with the established markers CA50, CA 19-9
and CEA.
Materials and methods
The C242 MAb and C50 MAb were obtained by immunisa-
tion of Balb/c mice with the human adenocarcinoma cell line
COLO205 (ATCC) and fusion of splenocytes with Sp 2/0
myeloma cell line (Lindholm et al., 1983). The monoclonal
antibodies were purified from in vitro cultivations of the
hybridomas by Protein-A affinity chromatography according
to recommendations of the manufacturer (Pharmacia LKB
Biotechnology, Uppsala, Sweden).
Microtiter plates were obtained from EF-Lab, Helsinki,
Finland. Isothiocyanato-benzyl-diethylenetriamine-tetraacetic
acid Eu chelate and other components used in DELFIATM
assays were obtained from Pharmacia Wallac Oy, Turku,
Finland. CEA DELFIATm and CA50 DELFIATM test kits
were obtained from Pharmacia Diagnostics AB, Uppsala
Sweden, and CA 19-9 test kits were purchased from Cen-
tocor, Malvern, US. Bovine serum albumin, RIA grade, was
purchased from Sigma Chemicals, St Louis, Mp, US. All
other chemicals were of analytical quality and used without
further purification.
Clinical material
A survey of the clinical material is given in Table I. CA242
and CA50 were analysed in totally 1,580 patients. CEA and
CA 19-9 were analysed according to the manufacturers in-
structions in part of the material (see results).
The serum samples were obtained by venipuncture and
stored at - 20°C before analysis. The samples from cancer
patients were obtained at diagnosis. The cancer diagnosis was
verified by histo-pathological examination, and the staging of
CRC was performed according to Dukes (Dukes & Bussey,
1985). The Dukes D relates to patients with metastatic and/
or locally advanced disease with overgrowth to adjacent
organs. The diagnosis of the other patients was obtained by clinical examinations.
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Table I Survey of the clinical material used for determination of
CA242 concentration
Diagnosis n Diagnosis n
Healthy subjects Malignant disease
Blood donorsa 200 Colo-rectal ca
Smokers" 100 Dukes A 98
Benign disease Dukes B 149
Ulcerative colitis 144 Dukes C 133
Adenoma 14 Dukes D 97
Liver cirrhosis 62
Pancreatitis 44
Obstr. biliary dis 31 Pancreatic ca 56
Other G.I. diseasec 28 Gastric ca 43
Surgical ward pat. 44 Cholangiocellular ca 28
Other benign dis.d 131 Other cae 185
aUnselected blood donors; bBlood donors smoking >20 cig/day;
clncluding diverticulosis, unspecifiedG-I pain, benign pancreatic cysts,
ulcus duodeni; dIncluding pneumonia, rheumatoid arthritis, prostatic
hypertrophy; 'Including oesophagus cancer, lung ca, prostatic ca,
urinary bladder ca, renal ca.
Design ofa DELFIAT assayfor determination ofCA242
The assay was developed as a forward sandwich assay, using
the C50 MAb as solid-phase catching antibody and Eu-
labelled C242 MAb as detecting antibody.
The microtiter wells of 8 x 12 wells strip plates were
coated with ; I tLg of C50 MAb in 200itl buffer essentially
as described previously (Lovgren et al., 1984). The coated
plates were stored sealed at +4°C and were stable for more
than 6 months. The C242 MAb was labelled with the Eu-
chelate of isothiocyanatobenzyl-diethylenetriamine-tetraacetic
acid to a specific activity of 3-5 Eu/molecule as described
(Hemmila et al., 1984). Tissue culture supernatant of
COLO 205 cells cultivated to confluency in Iscoves media
containing 5% foetal calf sera was used as antigen source for
standardization of the assay. The spent medium was diluted
in TBS-6% BSA to the arbitrary concentrations of 0, 5, 15,
50, 150 and 300 U ml-'. A reference preparation of tissue
culture supernatant of COLO 205 defined as having the con-
centration 500 U ml-' was used for calibration of the stan-
dards.
The assay procedure was as follows: 20 1l of standards or
samples were pipetted in duplicates into the C50 MAb coated
microtiter wells and 200 lI of DELFIATm Assay Buffer was
added; after 2 h incubation at room temperature with con-
stant shaking the wells were washed three times with Delfia
Wash Solution; 200 Al of europium labelled C242 MAb,
diluted in Assay Buffer to 0.5 tLg ml-', was added and the
incubation continued for another 1 h; the wells were washed
six times and the fluorescence intensity was determined in an
ArcusTM fluorometer after incubation with 200 Il Enhance-
ment Solution..
Analyticalperformance ofthe CA242 Delfia assay
The reproducibility of the assay was determined by analyses
of five samples in replicates of six during 5 days and
analytical precision by determination of CV% of duplicates
during routine analyses of clinical samples. Recovery of
CA242 antigen was determined by analyses of normal sam-
ples before and after addition of known amounts of CA242
antigen, and the linearity of the assay by analyses of dilu-
tions of elevated samples using Assay Buffer as sample
diluent.
Determination ofstatistical significances, and sensitivity and
specificity
Analyses of statistical significances were performed with Wil-
coxon non-parametric rank test. The statistical comparisons
between CA50 and CA242 were performed on paired sam-
ples, while the other statistical comparisons were performed
on unpaired samples.
The sensitivity of the different assays at different dis-
criminator levels was calculated as the fraction of tests
positive among the diseased population (TP/TP + FN), and
specificity as the fraction of tests negative among the ref-
erence population (TN/TN + FP) (Sunderman, 1975). The
sensitivity and specificity of the different tumour marker
assays were compared by 'Receiver Operated Characteristic'
(ROC) analyses (Sunderman, 1975; Metz, 1978).
The sensitivity and specificity of CA242 and CA50 in CRC
Dukes A-D was compared by ROC analyses using patients
with ulcerative colitis, adenomas, obstructive biliary disease,
other surgical ward patients of similar age as the cancer
patients and patients with miscellaneous G-I disease as
reference population (the number of patients is given in
Table I). The sensitivity and specificity of CA242 and CA50
in pancreatic cancer were determined using patients with
pancreatitis, liver cirrhosis, obstructive biliary disease, miscel-
laneous G-I disease and other surgical ward patients as
reference group.
Sensitivity and specificity of CA242 (and CA50) in com-
parison with CA 19-9 was compared by ROC analyses of
results from 81 patients with CRC and 132 patients with
benign gastro-intestinal disease. CEA was analysed in 290
patients with CRC (57 Dukes A, 93 Dukes B, 77 Dukes C
and 63 Dukes D), 54 cases with pancreatic cancer and in 174
of the patients with benign gastro-intestinal disease.
Results
Analyticalperformance
The CA242 Delfia assay gave a linear dose-response up to
300 U ml', with a CV% of less than 7% over the whole
standard curve range (Figure 1). The inter assay precision
showed that t90% of duplicates had a CV% <7.5% and
t95% of duplicates had CV% <10% (Table II). The
analytical sensitivity of the assay, defined as the concentra-
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Figure 1 Dose-response and precision profile of the CA242
Delfia assay. The dose-response and precision profile were based
upon determination of standards (and 1/2 and 1/5 dilution of
std 5 U ml-') using random pipetting of the standards on one
plate. The CV% was calculated from 12 replicates of each stan-
dard. 0 CPS; * CV%.
Table II Inter assay precision of CA242 DELFIA based upon
determination of CV% of duplicates
CV% n %
0 - 2.5 134 59.3
2.6- 5.0 54 23.9
5.0- 7.5 13 5.8
7.5- 10.0 14 6.2
10 -15 6 2.7
>15 5 2.2
Total 226 100
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tion corresponding to the signal of the 0-standard + 3 s.d.
was <0.5 U ml~-'.
The reproducibility study showed a total CV% of less than
7% in all but one sample (Table III). Serial dilution of five
elevated samples showed agreement between observed and
expected value indicating the same linearity of patient sam-
ples and standards (data not shown). The recovery ofantigen
added to normal serum samples varied from 92.4-109.5%
with a mean recovery of 99.6% of the added amount of
antigen (data not shown).
>1000-
500-
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Clinicalperformance
Distribution of CA242 in healthy subjects, benign and malig-
nant disease The distribution of CA242 in populations of
healthy subjects, benign and malignant disease is summarised
in Table IV and shown in Figure 2. The mean value of
CA242 in unselected blood donors and blood donors smok-
ing >20 cig/day was 7.1 ± 5.7 Uml-' and 6.1 ± 4.1 U ml-',
respectively, with levels ranging from 1-28 U ml-'. There
was no significant difference between smoking and unselected
blood donors. Ninety-five per cent of the healthy subjects
had CA242 levels below 19Uml-1.
Slightly elevated CA242 levels were found in subjects with
04 Table III Inter assay reproducibility
Mean ± s.d Total
Sample Replicates Uml1' CV%
1 30 6.6 ± 0.37 5.5
2 30 6.4 + 0.42 6.6
3 30 7.7 0.42 5.5
4 30 65.4 ± 2.94 4.5
5 30 140.3 5.19 3.7
6 30 6.0 ± 0.62 10.4
7 30 7.4 0.45 6.1
8 30 7.2 i 0.36 5.0
9 30 71.3 1.78 2.5
10 30 147.0 2.94 2.0
Thereproducibility wasdetermined byanalysesoffive serum(sample
1-5) and five plasma (6-10) samples in replicates ofsix during 5 days.
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Figure 2 a, CA242 level in normal subjects and benign gastro-
intestinal disease. For blood donors mean + 2 s.d. is shown. b,
CA242 levels in normal subjects and in colo-rectal, gastric, pan-
creatic and cholangiocellular carcinomas.
Table IV Concentration ofCA242 in normals, benign and malignant
disease
Mean ± s.d. Median
Diagnosis n Uml1' U ml-' Range
Healthy subjects
Blood donors 200 7.1 ± 5.7 5.4 1-27
Smokers 100 6.1 4.1 4.9 1-28
Benign disease
Ulcerative col 144 10.4 ± 13.2 6.4 1-108
Adenoma 14 9.3 8.1 6.7 2-30
Cirrhosis 62 9.0 ± 8.5 5.8 1-64
Pancreatitis 44 12.5 ± 15.9 7.0 1-90
Obst. bil. dis. 31 8.6 7.3 6.0 1-27
Other G.-I. dis.5 28 14.4 20.6 7.9 1-95
Surg ward pat 44 7.9 5.5 6.0 1-26
Other benigna 131 10.3 12.0 6.5 1-95
Malignant disease
Colo-rectal ca
Dukes A 98 10.3± 10.1 7.0 1-52
Dukes B 149 23.0 53.8b 10.0 1-600
Dukes C 133 89.0 328.3c 17.0 1-2380
Dukes D 97 375.3 1034.9d 38.0 1-8900
Pancreatic ca 56 966.5 ± 2731.5 201.0 3-14,760
Gastric ca 43 220.2 557.1 23.9 1-2444
Cholangio cell ca 28 3718.1 + 12,589.1 87.5 1-65,070
Other cal 185 15.9 24.8 7.8 1-210
aSee Table I; bSignificantly higher than Dukes A, P<0.01; cSignificantlyhigherthanDukesB, P<0.001;'Significantlyhigherthan
Dukes C, P<0.001.
benign disease. However, the differences between the groups
with benign disease and healthy subjects were not statistically
significant.
In CRC the levels of CA242 correlated with the Dukes
stage with highest levels in patients with Dukes C and D.
There were no significant differences in CA242 concentration
between the group of patients with CRC Dukes A and the
patients with benign disease, while the levels in Dukes B, C
and D were significantly higher (Table IV, Figure 2). Highly
elevated levels were also found in patients with other gastro-
intestinal cancers, particularly pancreatic cancer, but also in
subjects with gastric cancer and cholangiocellular carcinomas
(Table IV and Figure 2). Moderately elevated levels of
CA242 were also found in subjects with other pancer diag-
noses, Table IV.
Sensitivity and specificity of CA242, and comparison with
CASO, CA 19-9 and CEA The levels of CA242 were
significantly lower than the levels of CA50 in patients with
liver cirrhosis (P<0.001), pancreatitis (P<0.05), obstructive
biliary disease (P<0.001) and other surgical ward patients
(P<0.001), while the CA242 levels were significantly higher
in Dukes B (P<0.1) and in Dukes C and Dukes D
(P<0.001) compared to CA50 (Table V). The ROC analyses
of CA242 in CRC in relation to benign gastro-intestinal
disease gave at the 90% tumour specificity level a sensitivity
of 14%, 30%, 46% and 61% in CRC Dukes A, Dukes B,
Dukes C and Dukes D, respectively (Figure 3). The corre-
sponding sensitivity for CA50 was 4%, 7%, 15% and 44%
(Figure 3). The discriminator level resulting in 90% tumour
specificity was 20 U ml-' for CA242 and 45 U ml-' for
CA50. In pancreatic cancer the ROC analyses showed a
sensitivity of 77% for CA242 and 83% for CA50 at the 90%
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Table V Comparison between CA242 and CA50 in benign and
malignant gastro-intestinal disease
CA242 CASO
Diagnosis n Mean ± s.d. Mean ± s.d.
Benign disease
Ulc. colitis 144 10.4 ± 13.2 11.8 ± 30.0
Liver cirrhosis 47 9.0± 8.5a 36.0 ± 40.0
Obstr. gall dis. 31 8.6 7.3a 25.3 ± 22.9
Pancreatitis 44 12.5 ± 15.9b 19.1 ± 19.2
Surg. ward pat. 44 7.9 ± 5.5a 15.9 ± 19.1
Malignant disease
Colo-rectal ca
Dukes A 98 10.3 10.1 9.9 10.3
Dukes B 149 23.0 53.8c 15.8 13.8
Dukes C 133 90.7 327.6d 41.0± 122.9
Dukes D 97 375.3 ± 1034.9d 264.8 ± 931.9
Pancreatic ca 56 966.5 ± 2731.5 1029.3 ± 2469.7
Cholangio cell ca 28 3718.1 ± 12,589.1 1609.2 ± 6269.8
Gastric ca 21 350.4 ± 774.2 213.6 ± 360.6
aSignificantly lower than CA50, P<0.001; bSignificantly lower than
CA50, P<0.01;cSignificantly higherthanCA50, P<0.1;dSignificantly
higher than CA50, P<0.001.
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Figure 4 ROC curves for CA242 and CA50 in pancreatic
cancer. The specificity determination was based upon analyses of
137 patients with benign G-I and pancreatobiliary disease (liver
cirrhosis, pancreatitis, obstructive biliary disease, unspecific GI
pain) and 44 surgical ward patients of similar age. The sensitivity
was determined in 56 patients with pancreatic cancer. A CA242;
* CA50.
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Figure 5 ROC curves for CA242, CA50 and CA 19-9 in CRC.
The specificity was calculated from analyses of 132 subjects with
benign G-I disease, and the sensitivity from analyses of 81 sub-
jects with colo-rectal cancer. * CA242, A CA50, * CA 19-9.
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Figure 3 ROC curves for CA242 and CA50 in CRC Dukes
A-D. The determination of specificity was based upon analyses
of 261 subjects with benign disease (144 ulcerative colitis, 31
obstructive biliary disease, 14 adenomas, 44 surgical ward
patients and 25 subjects with other benign G-I disease). The
sensitivity was determined from analyses of 98 subjects with
Dukes A, 149 Dukes B, 133 Dukes C and 97 Dukes D. The
dotted line shows the 90% tumour specificity.
tumour specificity level (Figure 4). A discriminator level of
22 U ml-' and 65 U ml-' for CA242 and CA50 was neces-
sary to obtain 90% tumour specificity.
The results of the sensitivity and specificity analyses of
CA 19-9, CA242 and CA50 are shown in Figure 5. Ninety
per cent tumour specificity was obtained using a cut-off level
of 50 U ml-', 20 U ml -' and 35 U ml1' for CA 19-9, CA242
and CA50, respectively, and the corresponding sensitivity was
23%, 35% and 24%, respectively (Figure 5). The combina-
tion of CA242 and CA 19-9 (or CA50) did not increase the
sensitivity compared to the use of CA242 alone.
The ROC analyses of CEA and CA242 in 290 cases with
CRC, 54 subjects with pancreatic cancer and 174 subjects
with benign disease are shown in Figure 6. The sensitivity in
CRC for CEA at 90% tumour specificity was 19%, 40%,
51% and 71% in Dukes A, Dukes B, Dukes C and Dukes D,
respectively, and for CA242 the corresponding sensitivity was
18%, 29%, 49% and 62%. In pancreatic cancer the sen-
sitivity of CEA was 41% and 80% for CA242. The combina-
tion of CEA and CA242 increased the sensitivity to 28%,
54%, 62% and 79% in Dukes A, Dukes B, Dukes C and
Dukes D, while in 9%, 15%, 38% and 52% of the subjects
both CEA and CA242 was elevated above the 90% tumour
specificity discriminator level (Table VI). The cut-off levels
needed to obtain 90% tumour specificity were 7 ytg 1' for
CEA and 22 U ml-' for CA242. The correlation between the
CEA and CA242 levels in CRC was low with correlation
coefficients ranging from 0.2-0.6 (Figure 7).
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Figure 6 ROC curves for CA242 and CEA in CRC Dukes
A-D. The specificity was determined from analyses of 141 sub-
jects with benign GI disease and 33 surgical ward patients. The
sensitivity was calculated from analyses of 57 subject with CRC
Dukes A, 93 Dukes B, 77 Dukes C and 63 Dukes D. The dotted
line shows the 90% tumour specificity.
Table VI Sensitivity ofCA242 and CEA in colorectal and pancreatic
cancer at the 90% tumour specificity level
Sensitivity %
CEA or CEA and
CEA CA242 CA242 CA242
Diagnosis n pos. pos. pos. pos.
Colo-rectal ca
Dukes A 57 19.3 17.5 28.1 8.8
Dukes B 93 39.8 29.0 53.8 15.1
Dukes C 77 50.6 49.4 62.3 37.7
Dukes D 63 69.8 61.9 79.4 52.4
Pancreatic ca 54 40.7 79.6 83.3 37.0
Discussion
The CA242 tumour marker is a sialylated carbohydrate
antigen, which has been shown to be co-expressed with CA50
on a mucinous type of antigen called CanAg (Johansson et
al., 1991; Baeckstrom et al., 1991). The exact chemical struc-
ture of the CA242 epitope is at present not known, but
CA242 is clearly different from CA50 as the C242 MAb does
not react with sialylated Lewisa nor with sialylated-lacto-N-
tetraose (Johansson et al., 1991). An additional evidence that
CA242 is chemically different from sialylated Lewisa is that
the C242 MAb cannot inhibit the binding of anti-sialylated
Lewisa antibodies (Johansson et al., 1991). The CA242 epi-
tope has not been detected in glycolipid extracts (Johansson
et al., 1991), but CA242 active oligosacharides can be
released from CanAg antigen by alkaline borohydride hy-
drolysis indicating that the oligosacharides are bound with a
0-glycosidic linkage to the protein core of the CanAg
antigen (0. Nilsson, unpublished observation).
The C50 MAb was used for catching of the CanAg antigen
in both the CA242 and CA50 assays, while the captured
antigen was determined using monoclonal antibodies with
different specificities in the two assays. Thus the design of the
two assays indicate that the same antigen was determined
and that the only difference was that different epitopes on the
CanAg antigen was determined.
The two assays have been calibrated against the same
reference preparation of antigen with an arbitarily defined
concentration of 500 U ml-'. This means that the Unit values
were equivalent in the two assays, and that differences in
Unit levels measured with the CA50 and CA242 assays may
be statistically analysed as paired samples.
Although the same antigen was determined in the CA242
and CA50 assays there were large differences between the
levels of the markers in benign gastro-intestinal disease and
in CRC. Benign hepato-biliary diseases are known to give
elevated levels of CA50 and CA 19-9 (Haglund et al., 1987;
Harmenberg et al., 1988; Touitou & Bogdan, 1988), which
was also confirmed in this study. In the CA242 assay slightly
elevated levels were found in the patients with hepato-biliary
disease, but the levels were significantly lower (P<0.001)
than in the CA50 assay. The number of false positive subjects
among patients with benign hepato-biliary diseases were not
higher than in other groups of benign disease using the
CA242 assay, indicating that the specificity of CA242 was
similar in hepato-biliary disease as in other benign diseases.
This was in contrast to the CA50 assay, where 39% of
patients with liver cirrhosis and 19% of patients with ob-
structive biliary disease showed levels above the 90% tumour
specificity cut-off (45 U ml-'), compared to 1.4% of patients
with ulcerative colitis.
The levels of CA242 were not only lower in benign gastro-
intestinal disease compared to CA50, but in CRC, the CA242
levels were in many cases higher than the CA50 levels. The
increased tumour specificity and the higher levels of CA242
in CRC compared to CA50 also drastically increased the
sensitivity in CRC. This was most clearly noticed in Dukes
A, Dukes B and Dukes C where the use of CA242 increased
the sensitivity at the 90% specificity level approximately three
times compared to CA50. In pancreatic cancer the increased
tumour specificity of CA242 did not increase the sensitivity
compared to CA50.
The CA242 and CA50 epitopes are co-expressed on mucin
antigens, (Johansson et al., 1991; Johansson et al., 1991b), but
these studies do not indicate whether the epitopes are expres-
sed on only one core protein. Characterisation of the mucin
antigen in the Colo 205 colon adenocarcinoma cell line has
demonstrated that the CA50 and CA242 epitopes are co-
expressed on different core proteins (Baeckstrom et al., 1991).
It is therefore not possible to deduce whether the increased
specificity and increased levels of CA242 in CRC is due to
low synthesis of a particular core protein carrying both the
CA50 and CA242 epitopes in benign conditions and high
synthesis of the 'CA50/CA242 core protein' in CRC, or if it
is due to differences in glycosylation of the same protein core
in benign and malignant tissues with a preferential expression
of CA242 in cancerous tissues.
The increased tumour specificity of CA242 compared to
CA50 found in the serological studies has also been demon-
strated in several histological studies suggesting that there are
differences in synthesis of the epitopes between benign and
malignant tissues (Ouyang et al., 1987; Haglund et al., 1989).
The monoclonal antibodies used in the CA50 and CA 19-9
assays have almost the same epitope specificity, the only
difference being that the 19-9 MAb is specific for the
sialylated Lewisa bloodgroup substance, whereas the C50
MAb also recognises sialylated lacto-N-tetraose (Magnani et
al., 1982; Nilsson et al., 1985). From the known epitope
specificity of the antibodies used in the CA 19-9 and CA50
assays similar specificity and sensitivity should be expected in
serological studies, and in agreement to CA50 an increased
sensitivity of CA242 compared to CA 19-9 should be ex-
pected in CRC. This was also confirmed in this study.
In CRC, CEA has been the tumour marker of choice, and
several studies have demonstrated the utility of detection of
recurrent CRC (Minton et al., 1985; Minton & Chevinsky,
1989). However, the sensitivity of CEA in particularly Dukes
A and Dukes B is low and there are needs to find additional
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Figure 7 Correlation between CA242 and CEA in CRC Dukes A-D.
markers which alone or in combination with CEA would
increase the serological sensitivity for diagnosis and detection
of recurrent CRC in patients where curative treatment would
be possible if the diagnosis is available at an early stage, e.g.
surgery of solitary liver metastases.
The results of this study show that although CEA gave
higher sensitivity in CRC than CA242, the combined use of
CEA and CA242 increased the diagnostic sensitivity con-
siderably compared to the use of CEA alone (; 50% in
Dukes A, -35% in Dukes B, t20% in Dukes C). The
results also clearly demonstrate that CEA and CA242 were
expressed independently of each other, which also indicates
that CA242 could be a valuable complement to CEA in
CRC.
This study indicates that CA242 could be a superior
marker compared to CA50 and CA 19-9 and a valuable
complement to CEA in diagnosis of CRC and prognosis
prediction. Another clinical use of tumour markers is for
monitoring of the effects of therapy and detection of recur-
rent disease. Further studies are necessary to evaluate the
clinical utility of CA242 in e.g. the follow-up of CRC. A
preliminary study of CEA and CA242 in follow-up of CRC
showed that in 15 out of 18 patients with proven recurrent
disease CA242 was elevated while CEA was elevated in 12
out of the 18 patients (E.H. Cooper, personal communica-
tion).
The excellent technical assistance of Ms Ulrika Dahlen and Mrs
Eva-Lena Blom is gratefully acknowledged.
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